The LEO Foundation
Established in 1984, the Foundation is the controlling owner of LEO Pharma and its main objective is to ensure the company's long-term development and success as a global leader in dermatology, delivering outstanding results.
Until 2021, the Foundation was the sole owner of LEO Pharma. In 2021, the Foundation welcomed Nordic Capital as a minority shareholder and partner to the Foundation, who remains the company’s long-term controlling owner. The partnership with Nordic Capital will further support LEO Pharma’s development and strengthen its position in medical dermatology.
Learn more about the LEO Foundation >
Key LEO milestones:
  |
1908 LEO Pharma founded by two Danish pharmacists |
| 1910 3 employees |
|
| 1912 First product, Albyl, is marketed |
|
| 1926 80 employees |
|
| 1940 Heparin LEO® is launched |
|
 |
1945 LEO® Penicillin is marketed |
| 1958 Rontul® and Centyl® are marketed |
|
| 1958-1967 LEO expands to France, Holland, Ireland, the UK, Norway, Sweden and Belgium |
|
| 1962 Fucidin® is launched |
|
| 1978 One-Alpha® is launched |
|
| 1983 The LEO Foundation is established |
|
| 1984 LEO Canada opens |
|
| 1991 Dovonex® and innohep® are launched |
|
| 1994 3000 employees worldwide |
|
 |
2001 Dovobet® is launched |
 |
2008 100-year anniversary Expansion to China LEO 'Going for Gold' strategy announced |
| 2010 Operations in Brazil, Japan and Mexico initiated |
|
| 2012 Picato® is launched |